Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Pediatr Gastroenterol Nutr. 2024 Apr;78(4):871-877. doi: 10.1002/jpn3.12142. Epub 2024 Feb 14.
Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.
患有早发性炎症性肠病 (VEO-IBD) 的儿童对 2019 年冠状病毒病 (COVID-19) 免疫接种的反应可能与健康儿童或其他 IBD 患者不同。我们招募了在接种严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗后患有 VEO-IBD 的 <6 岁以下儿童。收集了人口统计学、IBD 特征、药物使用、不良事件 (AE) 和 IBD 加重情况。对部分参与者进行了血液检测，以测量接种疫苗后抗受体结合域 (RBD) IgG 抗体。在 41 名参与者中，无人因 AE 而需要急诊就诊或住院治疗，仅有 1 人发生 IBD 加重。提供血液样本的 19/19 名参与者均存在可检测抗体；6/7 名参与者 (86%) 在接种疫苗后 12 个月仍具有持久的体液免疫应答。患有 VEO-IBD 的儿童对 COVID-19 免疫接种具有强大的体液免疫反应。严重 AE 罕见。这些发现表明，VEO-IBD 儿童对 SARS-CoV-2 疫苗接种的反应良好且安全。
